hospital virus covid-19 patient

Glenmark says Phase 3 Favipiravir data for Covid-19 shows multiple benefits

Reading now: 401
www.livemint.com

International Journal of Infectious Diseases, the company said in a stock exchange filing. The Phase 3 study with Favipiravir, sold under the brand name FabiFlu, by the company was conducted in 150 patients, it added."The study aimed to evaluate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19," said the company.Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy, Glenmark said."Additionally, patients of confirmed.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA